This proposal for a Cancer Center Support Grant (CCSG) requests funding to support the cancer research activities of the Kimmel Cancer Center (KCC) in order to increase the survival and quality of life of cancer patients by translating basic research discoveries into new strategies to prevent, diagnose, monitor and cure human cancer. The major thrust of the Kimmel Cancer Center is in discovery and translation of discoveries in the genetics, cell biology, biochemistry and immunology of cancer into novel modalities to cure cancer. The Kimmel Cancer Center consists of seven Programs and fifteen Shared Resources to support the research programs. Investigators in each Program are involved in intraprogrammatic and interprogrammatic collaborations and have been extremely successful in obtaining peer reviewed funding for these collaborative studies. The collaborative environment within the KCC has facilitated numerous collaborative studies and publications that have contributed to important advances in cancer research. The KCC Programs are supported by $30 million in annual direct costs from NCI approved peer reviewed funding with $18 million of that funding coming from 95 NCI sponsored projects, including eight interprogrammatic NCI program project grants. The efforts of the Director and his recruits have resulted in a considerable increase in philanthropic and University support, NCI funding, and in the decision by Thomas Jefferson University to build a new KCC facility of approximately 500,000 square feet that will accommodate the basic, clinical and translational efforts of the KCC investigators. This new KCC facility will enhance even further the translational cancer research effort of the Kimmel Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA056036-08S2
Application #
7462925
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1995-06-22
Project End
2008-05-31
Budget Start
2005-06-01
Budget End
2008-05-31
Support Year
8
Fiscal Year
2007
Total Cost
$4,309,306
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603

Showing the most recent 10 out of 807 publications